Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PnuBioVax vaccine to prevent pneumococcal serotype 3 carriage in a controlled human infection model
PACTR202410920145275Phase 2Unknown
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of pnubiovax, Prevnar 13 and Normal Saline-Benha University (3 arms), sponsored by Liverpool School of Tropical Medicine. Primary endpoint: Experimental human pneumococcal carriage. Status: unknown.
02
Drugs
pnubiovaxPrevnar 13Normal Saline-Benha University
Beyond the preview
Go deeper on PACTR202410920145275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202410920145275.